Vepdegestrant is an investigational, orally bioavailable PROTAC estrogen receptor degrader. In the VERITAC-2 Phase 3 study, vepdegestrant demonstrated statistically significant and clinically ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein ...

The MarketWatch News Department was not involved in the creation of this content. Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status ...

Highly efficacious vaccines against COVD-19 have been generated in a record time, and allowed a great impact in preventing severe disease due to SARS-CoV-2 infection in vaccinated individuals.

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

SAN DIEGO, Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...